A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors

Jillian Johnson, Joshua A. Rash, Tavis S. Campbell, Josée Savard, Philip R. Gehrman, Michael Perlis, Linda E. Carlson, Sheila N. Garland

Research output: Contribution to journalReview article

75 Citations (Scopus)

Abstract

This review examined the efficacy of cognitive behavior therapy for insomnia (CBT-I) in people diagnosed with cancer. Studies were identified through November 2014 using multiple databases, clinical trial records, and bibliography searches. Inclusion was limited to randomized controlled trials of CBT-I conducted in individuals with a cancer diagnosis who had clinically relevant insomnia. The primary outcome variable was sleep efficiency (SE) as measured by sleep diary. Eight studies including data from 752 cancer survivors met inclusion criteria. CBT-I resulted in a 15.5% improvement in SE relative to control conditions (6.1%) from pre- to post-intervention, with a medium effect size (ES: d = 0.53). Overall, sleep latency was reduced by 22 min with an ES of d = 0.43, compared to a reduction of 8 min in the control conditions. Wake after sleep onset was reduced by 30 min with an ES of d = 0.41, compared to 13 min in the control conditions. Large effect sizes were observed for self-reported insomnia severity (d = 0.77) for those patients who received CBT-I, representing a clinically relevant eight point reduction. Effects were durable up to 6 mo. The quality of the evidence supports a strong recommendation for the use of CBT-I among cancer survivors.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalSleep Medicine Reviews
Volume27
DOIs
StatePublished - Jun 1 2016

Fingerprint

Sleep Initiation and Maintenance Disorders
Cognitive Therapy
Survivors
Meta-Analysis
Randomized Controlled Trials
Sleep
Neoplasms
Bibliography
Clinical Trials
Databases

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Johnson, Jillian ; Rash, Joshua A. ; Campbell, Tavis S. ; Savard, Josée ; Gehrman, Philip R. ; Perlis, Michael ; Carlson, Linda E. ; Garland, Sheila N. / A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. In: Sleep Medicine Reviews. 2016 ; Vol. 27. pp. 20-28.
@article{491de765f66e445892a3eeba2b4a640e,
title = "A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors",
abstract = "This review examined the efficacy of cognitive behavior therapy for insomnia (CBT-I) in people diagnosed with cancer. Studies were identified through November 2014 using multiple databases, clinical trial records, and bibliography searches. Inclusion was limited to randomized controlled trials of CBT-I conducted in individuals with a cancer diagnosis who had clinically relevant insomnia. The primary outcome variable was sleep efficiency (SE) as measured by sleep diary. Eight studies including data from 752 cancer survivors met inclusion criteria. CBT-I resulted in a 15.5{\%} improvement in SE relative to control conditions (6.1{\%}) from pre- to post-intervention, with a medium effect size (ES: d = 0.53). Overall, sleep latency was reduced by 22 min with an ES of d = 0.43, compared to a reduction of 8 min in the control conditions. Wake after sleep onset was reduced by 30 min with an ES of d = 0.41, compared to 13 min in the control conditions. Large effect sizes were observed for self-reported insomnia severity (d = 0.77) for those patients who received CBT-I, representing a clinically relevant eight point reduction. Effects were durable up to 6 mo. The quality of the evidence supports a strong recommendation for the use of CBT-I among cancer survivors.",
author = "Jillian Johnson and Rash, {Joshua A.} and Campbell, {Tavis S.} and Jos{\'e}e Savard and Gehrman, {Philip R.} and Michael Perlis and Carlson, {Linda E.} and Garland, {Sheila N.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.smrv.2015.07.001",
language = "English (US)",
volume = "27",
pages = "20--28",
journal = "Sleep Medicine Reviews",
issn = "1087-0792",
publisher = "W.B. Saunders Ltd",

}

A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. / Johnson, Jillian; Rash, Joshua A.; Campbell, Tavis S.; Savard, Josée; Gehrman, Philip R.; Perlis, Michael; Carlson, Linda E.; Garland, Sheila N.

In: Sleep Medicine Reviews, Vol. 27, 01.06.2016, p. 20-28.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors

AU - Johnson, Jillian

AU - Rash, Joshua A.

AU - Campbell, Tavis S.

AU - Savard, Josée

AU - Gehrman, Philip R.

AU - Perlis, Michael

AU - Carlson, Linda E.

AU - Garland, Sheila N.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - This review examined the efficacy of cognitive behavior therapy for insomnia (CBT-I) in people diagnosed with cancer. Studies were identified through November 2014 using multiple databases, clinical trial records, and bibliography searches. Inclusion was limited to randomized controlled trials of CBT-I conducted in individuals with a cancer diagnosis who had clinically relevant insomnia. The primary outcome variable was sleep efficiency (SE) as measured by sleep diary. Eight studies including data from 752 cancer survivors met inclusion criteria. CBT-I resulted in a 15.5% improvement in SE relative to control conditions (6.1%) from pre- to post-intervention, with a medium effect size (ES: d = 0.53). Overall, sleep latency was reduced by 22 min with an ES of d = 0.43, compared to a reduction of 8 min in the control conditions. Wake after sleep onset was reduced by 30 min with an ES of d = 0.41, compared to 13 min in the control conditions. Large effect sizes were observed for self-reported insomnia severity (d = 0.77) for those patients who received CBT-I, representing a clinically relevant eight point reduction. Effects were durable up to 6 mo. The quality of the evidence supports a strong recommendation for the use of CBT-I among cancer survivors.

AB - This review examined the efficacy of cognitive behavior therapy for insomnia (CBT-I) in people diagnosed with cancer. Studies were identified through November 2014 using multiple databases, clinical trial records, and bibliography searches. Inclusion was limited to randomized controlled trials of CBT-I conducted in individuals with a cancer diagnosis who had clinically relevant insomnia. The primary outcome variable was sleep efficiency (SE) as measured by sleep diary. Eight studies including data from 752 cancer survivors met inclusion criteria. CBT-I resulted in a 15.5% improvement in SE relative to control conditions (6.1%) from pre- to post-intervention, with a medium effect size (ES: d = 0.53). Overall, sleep latency was reduced by 22 min with an ES of d = 0.43, compared to a reduction of 8 min in the control conditions. Wake after sleep onset was reduced by 30 min with an ES of d = 0.41, compared to 13 min in the control conditions. Large effect sizes were observed for self-reported insomnia severity (d = 0.77) for those patients who received CBT-I, representing a clinically relevant eight point reduction. Effects were durable up to 6 mo. The quality of the evidence supports a strong recommendation for the use of CBT-I among cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=84943327597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943327597&partnerID=8YFLogxK

U2 - 10.1016/j.smrv.2015.07.001

DO - 10.1016/j.smrv.2015.07.001

M3 - Review article

C2 - 26434673

AN - SCOPUS:84943327597

VL - 27

SP - 20

EP - 28

JO - Sleep Medicine Reviews

JF - Sleep Medicine Reviews

SN - 1087-0792

ER -